Segall Bryant & Hamill, LLC Grifols Sa Transaction History

Segall Bryant & Hamill, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$15.4 - $20.16 $513,389 - $672,073	-33,337 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$18.24 - $21.45 $1.03 Million - $1.22 Million	-56,691 Reduced 62.97%	33,337 $608,000
Q1 2020 May 14, 2020	SELL	$16.28 - $25.63 $153,846 - $242,203	-9,450 Reduced 9.5%	90,028 $1.81 Million
Q4 2019 Feb 11, 2020	SELL	$19.57 - $23.52 $11,937 - $14,347	-610 Reduced 0.61%	99,478 $2.32 Million
Q3 2019 Nov 12, 2019	SELL	$19.85 - $22.76 $404,443 - $463,735	-20,375 Reduced 16.91%	100,088 $2.01 Million
Q2 2019 Aug 14, 2019	SELL	$17.59 - $21.1 $261,545 - $313,735	-14,869 Reduced 10.99%	120,463 $0
Q1 2019 May 15, 2019	BUY	$18.01 - $20.11 $62,080 - $69,319	3,447 Added 2.61%	135,332 $0
Q4 2018 Feb 15, 2019	SELL	$17.44 - $21.53 $119,324 - $147,308	-6,842 Reduced 4.93%	131,885 $2.42 Million
Q3 2018 Nov 14, 2018	SELL	$19.97 - $21.96 $144,063 - $158,419	-7,214 Reduced 4.94%	138,727 $0
Q2 2018 Aug 08, 2018	BUY	$20.16 - $24.68 $2.94 Million - $3.6 Million	145,941 New	145,941 $0

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.